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2Abstract
Aims
Paediatric guidance on diagnosis and treatment of urinary tract infections (UTIs) has in the
past largely focused on identifying children with vesicoureteral reflux, thought to be at
greatest risk of renal scarring. This practice has been questioned; specifically the accepted
association between UTI and end-stage renal failure (ESRF) through renal scarring. The aim
of this paper is to ascertain whether we can predict with confidence the true level of risk
that a child with a first time UTI will subsequently develop ESRF attributable to UTI.
Methods
Using data available from renal registries an analytical approach based on previous
estimates of risk is used to demonstrate the range of plausible estimates of risk that can be
generated and levels of uncertainty that surrounds those estimates.
Results
Estimates of the perceived risk of developing ESRF following UTI range from 1/154 to
1/199900 and are heavily dependent on the assumptions made and the source of data.
Conclusion
There is considerable uncertainty in the relationship between childhood UTI and risk of ESRF
based on the data currently available. Until further evidence is available clinicians will
continue to debate the risk of UTI and ESRF and consensus opinion will continue to guide
management.
Summary
Scarring of the kidneys can lead to ESRF. Most scarring is congenital, though some is caused
by childhood urinary tract infection. Invasive investigations are undertaken in the belief that
infection may lead to ESRF. We show that the risk of childhood urinary tract infection
leading to ESRF is highly uncertain. The routine use of invasive investigations may be
unwarranted based on the strength of the current evidence.
3Background
Urinary tract infection (UTI) is estimated to have been diagnosed in up to 11.3% of girls and
3.6% of boys by the age of 16 years in the UK(1) with recurrence common(2). Studies from
Sweden have shown incidence of first diagnoses of UTI to be around 2% of boys and girls by
the age of two years and 2% and 7% by the age of six years(3;4).
Of major importance in diagnosing and treating UTI is the perceived risk of renal scarring
resulting from febrile UTI, ultimately leading to end-stage renal failure (ESRF) and premature
death. How often episodes of febrile UTI in childhood could lead to end-stage renal failure
is of major interest as this would strongly influence the need for follow-up and radiological
investigations in these children. A widely cited 1997 study, by Stark(5), estimates that the
likelihood of UTI leading to ESRF in females was 1 in every 10,000 patients. The arguments
used to support this estimate are erroneous in that they use the incidence of new cases of
ERSF per year, rather than prevalence. As a result, the study describes the risk of someone
with a childhood UTI developing ESRF during one year, rather than the lifetime risk of
developing ESRF.
The 1997 study additionally fails to account for uncertainty in the relationship between
febrile UTI and renal scarring and the proportion of ESRF cases that can be attributed to UTI.
Any estimates of the risk of UTI leading to ESRF should take account of this uncertain
relationship.
Using the method of analysis employed in the Stark study as a starting point, this study
examines the lifetime risk of developing ESRF following a childhood UTI as well as
considering the uncertainty inherent in any such estimate to determine whether we can
predict with confidence the true level of risk.
Methods
Working from the information provided in the Stark study, described below are the methods
used to derive the original estimates of the risk of UTI leading to ESRF of 1/10,000. The same
analytic approach is then used to demonstrate, based on currently available data, the wide
range of plausible estimates of risk that can be generated and therefore the significant levels
4of uncertainty that surrounds any estimate of risk. Estimates of risk based on the data
collected across a range of countries are also calculated.
Data was collected from a range of renal registries(6-10). It was found that there is wide
variation in the diagnosis reported as the cause of ESRF resulting from acquired renal
scarring and congenitally dysplastic kidneys. In The United Kingdom the renal register
reports do not distinguish between congenital and acquired cases and attribute all cases to
the diagnosis of pyelonephritis. The European Renal Association – European Dialysis and
Transplant Association (ERA-EDTA) register also reports cases as pyelenophritis, again
without distinction in the reported figure between congenital and acquired cases. In
Australia and New Zealand these cases are attributed to reflux nephropathy, again without
distinction between acquired and congenital cases. In data from the United States Renal
Data System (USRDS) a more detailed breakdown of the causes of ESRF is provided and a
distinction is made between those causes related to acquired or congenital scarring
(including six different diagnoses for various forms of obstructive or non-obstructive
congenital malformations). They do however use the headings of interstitial
nephritis/pyelonephritis, chronic pyelonephritis and reflux nephropathy which encompasses
both congenital and acquired cases.
Three patient populations are included in the analysis: those with UTI (both febrile and non-
febrile), those with renal damage associated with vesicoureteral reflux (VUR) and those with
ESRF.
Within Figure 1 the population of interest is the proportion of patients who develop ESRF
given that they have had a UTI in childhood; this population is represented by area (B+D). In
calculating the risk for this population:
i. Lifetime risk of UTI = (B+D+E+G)
ii. Prevalence of ESRF = (A+B+C+D)
iii. ESRF attributable to renal damage associated with VUR = (B+C)
5iv. Proportion of ESRF attributable to renal damage associated with VUR =
(B+C)/(A+B+C+D)
v. Risk of UTI leading to ESRF = (B+D) / (B+D+E+G)
The initial, base case analysis, based on that of Stark(5), assumes for all cases of ESRF
attributed to renal damage the patient has had a UTI (C=0) and secondly, that renal damage
associated with VUR is the only mechanism by which UTI can lead to ESRF (D=0). These
assumptions, while useful in the development of the base-case model, do not necessarily
reflect the true clinical situation but are retained to allow comparison with the analysis by
Stark(5).
Re-analysis using this method is conducted to demonstrate the wide range of plausible
alternative estimates, drawing on data available from renal registries and the published
literature. Stark bases his analysis on the annual incidence of ESRF, whereas the cumulative
lifetime risk of developing ESRF may be more appropriate for estimating the risk of
childhood UTI leading to ESRF over the course of lifetime. We show how the choice of
annual incidence or cumulative incidence impacts on the estimate of risk. Estimates of risk
are for females and are applied to the proportion of the cohort at risk (those who were alive
and who had not already developed ESRF). Data for females is used in the first analysis to
allow comparison with the estimate made by Stark(5;11).
The five different models tested and the source of data for each are presented in Table 1.
The analysis by Stark is based on a mix of data from the USRDS and EDTA registries. Table 2
presents the cumulative incidence of ESRF calculated from EDTA figures. Table 3
demonstrates the risk of childhood UTI leading to ESRF based on estimates of cumulative
incidence of ESRF taken from Table 2. We start by presenting the analysis made by Stark and
then proceed to change the inputs into the model to show how different assumptions about
the parameter values in the model used to calculate risk impact on the model results.
We also present an international comparison of the risk of UTI as the cause of current cases
of ESRF to demonstrate how the definition of ESRF and its causes impacts on how risk may
be perceived on a country by country basis. Data for this analysis is used for the total
population and is based on prevalence of ESRF in the total population, as it was not possible
6to make like-for-like comparisons using incidence data between countries using the available
published evidence (Table 4).
Results
Table 2 shows the estimated lifetime risk for females of developing ESRF to be 5777 PMP as
calculated from estimates of incidence reported by the EDTA(7). The age group of interest is
likely to be represented by those patients under 60, as according to Stark, ESRF that occurs
after this age is unlikely to be attributable to a childhood UTI. Although no data is presented
by Stark(5)5 to support this assertion, it is plausible that as age increases, the role of
childhood UTI in the development of ERSF is more difficult to establish; 60 is used as a cut-
off in Models Two and Four to allow direct comparison of risk with Stark. In this particular
age group, the risk of developing ESRF during one’s lifetime is 2525 PMP.
The result of the Stark model is presented in Table 3 and represents the base-case scenario.
By substituting the whole life-time estimate based on the data from the EDTA in place of the
estimate of incidence from the USRDS as used by Stark, life-time risk for females developing
ESRF as a result of having had a childhood UTI is estimated at about 1/154 (Model 1). But
Model 1 does not arrive at a realistic estimate of the true risk, suggesting further deviation
from Stark’s previous estimate is required.
Stark chose an age cut-off of 60 years. While this is largely arbitrary, it is kept for sake of
comparison, as there is no evidence to suggest what an appropriate age cut-off would be.
For the group of patients under 60, the risk of UTI leading to ESRF is about 1/352 (Model 2).
When using the original estimate of risk of developing ESRF used by Stark and substituting a
revised estimate of renal scarring leading to ESRF from the USRDS data10, the risk is much
higher, at about 1/115,000 (Model 3). Using the USRDS figure of ESRF caused by renal
scarring and the risk of developing ESRF before the age of 60 from the EDTA data, the
estimate of risk is approximately 1/3960 (Model 4).
7Comparisons in Table 4 are based on the prevalence of ESRF across the whole population for
each country. This table shows the probability that any current case of ESRF may have been
associated with a UTI in childhood. Due to the differences in the way that data is reported
between countries, this estimate is based on the prevalence of ESRF at all ages. This will
most likely overestimate the risk of a childhood UTI leading to ESRF; however, there will still
exist differences in risk estimates arising from the way in which the causes of ESRF and those
patients with ESRF are defined in different countries and regions and it is the relative
differences that are of importance in the comparison made in Table 4.
Discussion
In this study we found that the risk of developing ESRF following a first time UTI in females is
uncertain and potentially much greater than that estimated in a previous study. Depending
on the assumptions we made in our model, we found estimates of risk to vary between
1/861 to 1/3300, with an outlying value of 1/199,900 when the data from the US register
USRDS was used. If the figures are calculated instead for patients with febrile UTI then the
risk will be substantially higher. Jodal et al(12) found that the incidence of febrile UTI by the
age of seven was 2.7% for girls, roughly one third the estimate of risk of any childhood UTI. If
only febrile UTI were considered each estimate of risk given above would between three and
four times greater.
It is well known that in particular circumstances UTI is associated with a risk of renal
scarring(13). This is estimated to occur in 5-15% of children within the two years of their first
presentation with a febrile UTI(2). Young children, especially infants, are assumed to be at
greater risk of developing renal scarring than older children or adults. Renal scarring is
known to be associated with long-term morbidities such as, pregnancy complications,
chronic kidney disease and in some cases, established ESRF. End stage renal failure is
irreversible and requires regular dialysis or transplantation if the individual is to survive(14).
A major problem when calculating the risks of a UTI is the difficulty in separating congenital
renal dysplasia from acquired scarring due to acute pyelonephritis. This is in many cases
both clinically and scientifically a very complex differential diagnosis. It was previously
8believed that acquired renal scarring was very common. With the advent of prenatal
ultrasound it has however become evident that much of this scarring was present at birth.
It is clear from this analysis that there are marked differences in attribution of causes of
ESRF across different countries. This is related to the diagnostic difficulties mentioned above
and makes it difficult to estimate the real likelihood that a childhood UTI will go on to cause
ESRF. It can be reasonably assumed that although the rates of UTI leading to ESRF differ
across countries, much of this difference may be attributable to the way that the causes of
ESRF are defined. To avoid this ambiguity, the analyses presented here includes an
international comparison to show where these differences arise and how they impact on the
results. For example, in Australia and New Zealand, 3% of ESRF cases are attributed to reflux
nephropathy, while in the UK, 12% of cases are attributed to pyelonephritis.
Within the analyses presented here, estimation of life-time risk of developing ESRF as a
result of having had a childhood UTI is highly variable; results are highly dependent on which
registry data is included in the analysis. The USRDS registry (as used in Model 3) provides the
greatest detail in defining the causes of ESRF. As a result, the model based on figures from
this registry provides arguably the most reliable estimate.
Stark argues that the number of patients who have a single UTI in childhood who then go on
to have ESRF is very small, and that the risk of developing ESRF as a result of a childhood UTI
is low5. This would suggest that the investigations often undertaken to diagnose VUR and
renal scarring in children with first-time UTI are unwarranted and significant changes in
clinical practice may be required, though such investigations may be warranted for reasons
unrelated to concerns about developing long-term complications such as ESRF. If risk cannot
be estimated reliably, the implications for the management of children who present with
symptoms suggestive of UTI become unclear.
The confusion about the risk of a UTI highlighted in the present analyses can significantly
explain the wide differences in opinion about how to manage children who have had this
infection. Over the past decade there has been a strong debate that has focussed on the
relationship between UTI, VUR and scarring. Venhola and Uhari(15) e.g. argue that ‘the
overall importance of VUR is confounded because of the natural tendency of VUR to resolve
9spontaneously, its dynamic nature, and its different grades in children’. In line with the
recently published UK guidelines from NICE(16) which outline a less invasive programme of
management, they recommend ‘less unpleasant and possibly unnecessary imaging tests for
VUR’(15). This is refuted by some professionals who argue for more rather than less
assiduous management given evidence and clinical anecdotes ‘which indicate that scars may
develop in infant kidneys quicker than urine culture can confirm the diagnosis, and that
reflux nephropathy has no age limit’(17).
Conclusion
Re-analysis of a previously published model shows that there is considerable uncertainty in
the relationship between childhood UTI and risk of ESRF based on the data currently
available. Until further evidence is available clinicians will continue to debate the risk of UTI
and ESRF and consensus opinion will continue to guide management. Registers that try to
separate acquired from congenital renal scarring are needed in order to establish the true
risk of childhood UTI leading to ESRF and to guide appropriate clinical management.
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Tables
Table 1: Summary of risk models and sources of data for each parameter
Model
Parameter Stark One Two Three Four
Annual Incidence of
ESRF
USRDS(5) N/A N/A USRDS(5) NA
Cumulative
incidence of ESRF
NA EDTA(7) EDTA(7) NA EDTA(7)
ESRF associated
with VUR
Stark(5) Stark(5) Stark(5) USRDS(8) USRDS(8)
Table 2: Cumulative incidence of ESRF: Females only (calculated from EDTA incidence figures(7))
Age band Number at
start
Mortality rate per
million per year
Number at
end
Number at
risk
Annual incidence of
ESRF per million
Number with
ESRF (new)
Cumulative
ESRF
0 to 1 1000000 4940 995060 997530 8.5 8 8
1 to 4 995051.5 240 994096.3 994573.9 8.5 34 42
5 to 9 994062.5 106 993535.6 993799 8.5 42 85
10 to 14 993493.4 106 992966.8 993230.1 8.5 42 127
15 to 19 992924.6 248 991693.4 992309 8.5 42 169
20 to 24 991651.2 248 990421.6 991036.4 38.2 189 358
25 to 29 990232.3 436 988073.6 989152.9 38.2 189 547
30 to 34 987884.6 436 985731 986807.8 38.2 188 736
35 to 39 985542.6 952 980851.4 983197 38.2 188 923
40 to 44 980663.6 952 975995.6 978329.6 38.2 187 1110
45 to 49 975808.8 2509 963567.3 969688 98.8 479 1589
50 to 54 963088.2 2509 951006.3 957047.3 98.8 473 2062
55 to 59 950533.5 5918 922407.2 936470.4 98.8 463 2525
60 to 64 921944.6 5918 894664.3 908304.4 98.8 449 2973
65 to 69 894215.6 16701 819544.1 856879.8 224.3 961 3934
70 to 74 818583.1 16701 750227.3 784405.2 224.3 880 4814
75 to 79 749347.6 51252 557319.8 653333.7 169.2 553 5367
80 to 84 556767.1 51252 414089.9 485428.5 169.2 411 5777
Table 2 adapted from the NICE guidelines on the management of UTI in children(16)
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Table 3: Risk of childhood UTI leading to ESRF(females only)
Stark Model 1 Model 2 Model 3 Model 4
Incidence of ESRF
(PMP)*
87 5777 2525 87 2525
Prevalence of UTI (%) 8.0 8.0 8.0 8.0 8.0
ESRF associated with
VUR (%)
9.0 9.0 9.0 0.49 0.49
Risk of UTI leading to
ESRF (as a ratio)
1/10217 1/154 1/352 1/114943 1/3960
Model 1: Incidence of ESRF is all ages; ESRF associated with VUR is based on EDTA data
Model 2: Incidence of ESRF is up to age 60; ESRF associated with VUR is based on EDTA data
Model 3: Incidence of ESRF is based on Stark estimate; ESRF associated with VUR is based on
USRDS data
Model 4: Incidence of ESRF is up to age 60; ESRF associated with VUR is based on USRDS
data
Table 4: Comparison of international risk estimates based on prevalence (based on all sex
and age groups)
Europe Australia
New
Zealand USA UK
Prevalence of ESRF (PMP) 662(9) 822(18) 808(18) 1665(8) 774(6)
Prevalence of UTI (%) 8.0(5) 8.0(5) 8.0(5) 8.0(5) 8.0(5)
ESRF due to renal scarring
associated with VUR (%) 9.0(9) 3.0(18) 3.0(18) 0.8(8) 12.0(6)
Risk of UTI leading to ESRF (as a
ratio) 1/1429 1/3244 1/3300 1/199900 1/861
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Figure Legends
Figure 1: Model of risk of UTI leading to ESRF
The populations represented in the Figure 1 are as follows:
1. Whole population: H
2. Patients that have had a childhood UTI: E+B+D+G
3. Patients with ESRF: A+B+C+D
4. Patients with Renal damage associated with VUR: B+C+E+F
5. Patients with ESRF that had a childhood UTI: B+D
6. Patients with ESRF and renal damage associated with VUR: B+C
7. Patients with ESRF and renal damage associated VUR and have had a childhood UTI :
B
